Skip to main content
. 2014 Mar-Apr;59(2):182–185. doi: 10.4103/0019-5154.127681

Table 2.

Conditions for discontinuation of itraconazole therapy in AIDS patients with disseminated histoplasmosis on highly active antiretroviral therapy

graphic file with name IJD-59-182-g006.jpg